All updated as on -
The global dry eye syndrome market was worth USD 3.9 billion in 2022, and it is expected to expand from USD 3.90 billion in 2023 to USD 5.36 billion by 2030, at a CAGR of 6.31% from 2023 to 2030. The primary market drivers boosting the market growth are the increasing prevalence of eye problems, changes in lifestyle, and developments in therapy.
Lack of sufficient quality tears to lubricate and nourish the eye is the root cause of Dry Eye Syndrome (DES), also known as Keratoconjunctivitis Sicca (KCS), a common ophthalmic illness. Redness, stinging, scratching, or burning sensation, sensitivity to light, watery eyes, stringy mucus surrounding the eye, and blurred vision are some of the symptoms. The prevalence of dry eye was 8.4% in those younger than 60 years old, 15% in those 70-79 years old, and 20% in those older than 80 years old, according to a study published in BMC Ophthalmology in February 2022.
In addition, age-related declines in lacrimal gland function contribute to the onset of this illness. Postmenopausal women have also shown increased rates of the illness. The overall prevalence of DED symptoms was 79%, and was increasing rapidly in postmenopausal women, according to a research released in June 2021 by the National Library of Medicine in a cohort of 1947 perimenopausal and postmenopausal women aged 45 to 79 years. During the projected period, the global market is expected to develop due to the rising need for therapeutic measures caused by these tendencies.
About 360 billion people in the globe suffer from dry eye disease, making it one of the most widespread ophthalmic disorders. Dry eyes cause discomfort, including redness, dryness, tiredness, and poor vision. Dry eyes syndrome is on the rise, especially among the young and the old, because to factors including the proliferation of digital devices, the popularity of contact lenses, poor nutrition, and the popularity of LASIK eye operations. The growth of the Dry Eye Syndrome Market is being driven by a number of factors, including improvements in treatment and lifestyle changes.
In addition, 73% of patients tested positive for tear MMP-9, and the average patient age was 57.8 years old, according to the clinical Ophthalmology journal in February 2021. Patients' symptoms and indicators improved dramatically after one month of treatment with topical corticosteroids, with improvements of up to 90.6%. This exemplifies the widespread prevalence of dry eye disease among the elderly. As a result, the global dry eye syndrome market's CAGR has been boosted by these elements in the recent years.
The rising prevalence of Mask-Associated Dry Eye (MADE) is a major development in the international market. Although face masks and face shields were essential in the fight against COVID-19, most ophthalmologists noticed an increase in the number of patients complaining of dry eyes during the epidemic. Additionally, after the COVID-19 epidemic, various medical groups observed an increase in occurrences of dry eye due to the widespread use of face masks. The trend towards mask use is projected to persist into the foreseeable future as the prevalence of other infectious diseases, especially those spread by the air, rises. The projected term is expected to see the market for these items expand as a result of the current trend.
The worldwide rise in this condition's incidence is one of the most important factors propelling the international market. This chronic illness becomes more common as people get older. However, the prevalence is rising in both the young and the old due to the rise in screen time, poor nutrition, contact lens use, and LASIK procedures. Dry eye syndrome is becoming more common, which has increased the need for effective treatments that improve patient outcomes. As more people in more places are able to get their hands on these goods, the market will expand. The expansion of the global market is expected to be fueled by the efforts of a number of market participants to increase their research operations and focus on obtaining regulatory approval of therapeutically effective innovative medicines.
Report Coverage
Global Dry Eye Syndrome research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Dry Eye Syndrome report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Dry Eye Syndrome competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Dry Eye Syndrome market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Dry Eye Syndrome market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Dry Eye Syndrome market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaseutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (US), Acadia Pharmaceuticals (US), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada)
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Dry Eye Syndrome market based on the below-mentioned segments:
Global Dry Eye Syndrome Market, By Type
Evaporative
Aqueous
Global Dry Eye Syndrome market, By Treatment
Nutritional Supplements
Surgery
Global Dry Eye Syndrome Market, By End User
Hospitals
Global Dry Eye Syndrome market, Regional Analysis
Lack of sufficient quality tears to lubricate and nourish the eye is the root cause of Dry Eye Syndrome (DES), also known as Keratoconjunctivitis Sicca (KCS), a common ophthalmic illness. Redness, stinging, scratching, or burning sensation, sensitivity to light, watery eyes, stringy mucus surrounding the eye, and blurred vision are some of the symptoms. The prevalence of dry eye was 8.4% in those younger than 60 years old, 15% in those 70-79 years old, and 20% in those older than 80 years old, according to a study published in BMC Ophthalmology in February 2022.
In addition, age-related declines in lacrimal gland function contribute to the onset of this illness. Postmenopausal women have also shown increased rates of the illness. The overall prevalence of DED symptoms was 79%, and was increasing rapidly in postmenopausal women, according to a research released in June 2021 by the National Library of Medicine in a cohort of 1947 perimenopausal and postmenopausal women aged 45 to 79 years. During the projected period, the global market is expected to develop due to the rising need for therapeutic measures caused by these tendencies.
About 360 billion people in the globe suffer from dry eye disease, making it one of the most widespread ophthalmic disorders. Dry eyes cause discomfort, including redness, dryness, tiredness, and poor vision. Dry eyes syndrome is on the rise, especially among the young and the old, because to factors including the proliferation of digital devices, the popularity of contact lenses, poor nutrition, and the popularity of LASIK eye operations. The growth of the Dry Eye Syndrome Market is being driven by a number of factors, including improvements in treatment and lifestyle changes.
In addition, 73% of patients tested positive for tear MMP-9, and the average patient age was 57.8 years old, according to the clinical Ophthalmology journal in February 2021. Patients' symptoms and indicators improved dramatically after one month of treatment with topical corticosteroids, with improvements of up to 90.6%. This exemplifies the widespread prevalence of dry eye disease among the elderly. As a result, the global dry eye syndrome market's CAGR has been boosted by these elements in the recent years.
The rising prevalence of Mask-Associated Dry Eye (MADE) is a major development in the international market. Although face masks and face shields were essential in the fight against COVID-19, most ophthalmologists noticed an increase in the number of patients complaining of dry eyes during the epidemic. Additionally, after the COVID-19 epidemic, various medical groups observed an increase in occurrences of dry eye due to the widespread use of face masks. The trend towards mask use is projected to persist into the foreseeable future as the prevalence of other infectious diseases, especially those spread by the air, rises. The projected term is expected to see the market for these items expand as a result of the current trend.
The worldwide rise in this condition's incidence is one of the most important factors propelling the international market. This chronic illness becomes more common as people get older. However, the prevalence is rising in both the young and the old due to the rise in screen time, poor nutrition, contact lens use, and LASIK procedures. Dry eye syndrome is becoming more common, which has increased the need for effective treatments that improve patient outcomes. As more people in more places are able to get their hands on these goods, the market will expand. The expansion of the global market is expected to be fueled by the efforts of a number of market participants to increase their research operations and focus on obtaining regulatory approval of therapeutically effective innovative medicines.
Report Coverage
Global Dry Eye Syndrome research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Dry Eye Syndrome report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Dry Eye Syndrome competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Dry Eye Syndrome market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaseutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (US), Acadia Pharmaceuticals (US), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada) |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Dry Eye Syndrome Market from 2021 to 2030.
- Market Forecast for Dry Eye Syndrome Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Dry Eye Syndrome competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Dry Eye Syndrome
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Dry Eye Syndrome market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Dry Eye Syndrome market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaseutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (US), Acadia Pharmaceuticals (US), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada)
Primary Target Market
- Market Players of Dry Eye Syndrome
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Dry Eye Syndrome market based on the below-mentioned segments:
Global Dry Eye Syndrome Market, By Type
Evaporative
Aqueous
Global Dry Eye Syndrome market, By Treatment
Nutritional Supplements
Surgery
Global Dry Eye Syndrome Market, By End User
Hospitals
Global Dry Eye Syndrome market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive dry eye syndrome market market research and competitor analysis for your business to help you develop more profound insights into the dry eye syndrome market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the dry eye syndrome market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.